Authors analyze efficiency of application antiseptics of a miramistin in prevention of infectious complications in case of repeated intravitreal injections of VEGF inhibitor Ranibizumab in 156 patients with the age related macular de-generation. 0,01% solution of antiseptic Miramistin (Okomistin®) was instillated 4 times per day two days before operation to all patients for the purpose of infection prevention. Just before the operation (60 and 30 minutes before) and right after it instillations of antiseptic continued within a week after intravitreal injection. During the operation in the conditions of the operating room with keeping of all rules of aseptic, three minutes prior to operation the surgery field and the conjunctival cavity of the patient were twice processed by 5% povidone-iodine solution (Betadine). The results analysis showed no expressed signs of irritation of the eyes connected to miramistin treatment preceding the operation. In the postoperative period all patients endured antiseptics well. Within a week of applications there were no complaints about pain, burning, foreign body sensation or hazy vision after the medicine instillation, and biomicroscopic research revealed no signs of inflammatory injection of conjunctiva or sclera, no cornea epitheliopathy, there was no cellular response in moisture of the anterior chamber and vitreous body. Thus, the authors state that antiseptics Okomistin® as an additional measure of prevention of infectious complications in case of intravitreal injection provide high level antimicrobic protection with no risk of development of microbial resistance.
intravitreal injections, endophthalmitis, prevention
1. BelousovYB (2010). Antibiotic therapy today [Antibiotikoterapiya segodnya]. Voprosy vrachebnoy praktiki, (9), 54-57
2. BoykoEV, SosnovskiySV (2013). Angiogenic therapy inophthalmology [Angiogennaya terapiya v oftal’mologii], 286.
3. VokhmyakovAV, OkolovIN, GurchenokPA (2007). Choosing the best antibiotic for prevention of infectious complications in ophthalmic surgery (review) [Vybor optimal’nogo antibiotika dlya profilaktiki infektsionnykh oslozhneniy v oftal’mokhirurgii (obzor literatury)]. Klinicheskaya oftal’mologiya, 1(8), 37-40.
4. GeysekL, StepanovAK, BeneshovaZ, NemetsP,ReymontL, ErnestY, RozsivalP (2013). Infectious complications of intravitreal VEGF inhibitors for the treatment of wet age-related macular degeneration [Infektsionnye oslozhneniya pri intravitreal’nom vvedenii ingibitorov VEGF pri lechenii vlazhnoy formy vozrastnoy makulyarnoy degeneratsii]. Rossiyskiy oftal’mologicheskiy zhurnal, (3), 20-24.
5. EgorovEA, GundorovaRA, KrivosheinYS, AlekseevaIB, SmoktiyYM, AsrorovaGK, GalchinAA (2003). Application of Miramistin in ophthalmology. The guidelines for physicians [Primenenie Miramistina v oftal’mologii. Posobie dlya vrachey], 8.
6. IoshinIE, TolchinskayaAI, TagievaRR, DubrovskayaSA(2011) The effectiveness of angiogenesis inhibitor Ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration [Effektivnost’ primeneniya ingibitora angiogeneza Ranibizumaba (Lutsentisa) v lechenii neovaskulyarnoy vozrastnoy makulyarnoy degeneratsii]. Rossiyskiy oftal’mologicheskiy zhurnal, (2), 21-27.
7. IoshinIE, TolchinskayaAI (2011). Prevention of infectious inflammatory complications in cataract phacoemulsification [Profilaktika infektsionnykh vospalitel’nykh oslozhneniy pri fakoemul’sifikatsii katarakty]. Eye World, 4(3), 52-53.
8. MaichukYF, SeliverstovaKE, YakushinaLN (2011) Antiseptic Okomistin in treatment of bacterial diseases of the eye [Antiseptik Okomistin v lechenii bakterial’nykh zabolevaniy glaz]. Kataraktal’naya i refraktsionnaya khirurgiya,11(2), 59-64.
9. OkolovIN, GurchenokPA (2008). Antibiotic re-sistance of normal flora of the conjunctiva of patients prior to ophthalmic operations [Rezistentnost’ k antibiotikam normal’noy mikroflory kon’yunktivy u patsientov pered oftal’mokhirurgicheskimi operatsiyami]. Oftal’mologicheskie vedomosti, 1(4), 59-62.
10. ESCRS guidelines on prevention and treatment of endophthalmitis after cataract surgery: data, dilemmas and conclusions (2013) [Rukovodstvo ESCRS po profilaktike i lecheniyu endoftal’mita posle udaleniya katarakty: dannye, dilemmy i vyvody]. Available at: www.escrs.org.
11. SaryginaOI, BychkovPA (2014) Prevention of infectious complications at intravitreal ranibizumab injections [Profilaktika infektsionnykh oslozhneniy pri intravitreal’nykh vvedeniyakh ranibizumaba]. Rossiyskiy oftal’mologicheskiy zhurnal, (2), 62-66.
12. StebnevSD (2012). Experience in the use of Okomistin medicine in pre- and postoperative period in patients with cataracts [Opyt ispol’zovaniya lekarstvennogo preparata Okomistin v pred- i posleoperatsionnom periode u patsientov s kataraktoy]. Oftal’mologiya, 9(4), 69-72.
13. BarryP, SealDV, GettinbyG, LeesF, PetersonM, RevieCW (2006). ESCRS study of prophylaxis of postoperative endophthalmitis after cataract Surgery: Preliminary report of principal results from a European multicenter study. J. Cataract Refract Surg., 32(3), 407-410.
14. MarangonFB, MillerD, MuallemMS (2004).Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am. J. Ophthalmol., 137(3), 453-458.
15. RegilloCD, BrownDM, AbrahamP, YueH,IanchulevT, SchneiderS. et al. (2008) Randomized, double-masket, sham-controlled trial of ranibizumab for neovascular age-relared macular degeneration: PIER Study year 1. Am. J. Ophthalmol., 145(2), 239-248.
